德琪醫藥-B(06996.HK)：成立AI部門，推動AnTenGager™平臺發展
格隆匯2月19日丨德琪醫藥-B(06996.HK)發佈公告，公司計劃加大投入，整合資源成立專門的AI部門。這一舉措包括本地部署DeepSeek以加速具有空間位元阻遮蔽效應的T細胞銜接器(TCE)平臺後續管線研發。
公司早在2021年便以天使投資人身份投資杭州德睿智藥AI藥物發現平臺，並藉此戰略性的切入了AI藥物發現賽道。這一戰略舉措使公司能夠在內部利用AI能力，並開發出若幹款小分子產品。同時公司也已通過AI資料模型結合多組學分析，成功發現全新肝癌相關抗原(TAA)並將其開發爲TCE候選藥物進入臨牀前驗證階段，從而使公司成爲利用AI進行藥物研發領域的先行者。
爲擴大優勢，公司計劃加大AI藥物研發方面的投入。通過整合過去4年已有資源，並當地語系化部署DeepSeek，公司將利用特定演算法和AI資料採集，對跨資料庫多組學資訊進行整合分析。這種方法可以對候選蛋白進行有效的排序遴選，鎖定適於TCE的全新腫瘤抗原以加速公司TCE平臺後續管線的研發。
AnTenGager™平臺是公司自主研發的具有空間位阻遮蔽效應的“2+1”TCE平臺，可旨在實現疾病相關抗原(DAA)依賴的T細胞結合和啓動。這種方法可以在實現較強的治療活性的同時降低發生細胞因子風暴的風險。通過二價結合DAA，該平臺開發的TCE能夠有效識別並深度清除低靶抗原表達水準的細胞。此外， AnTenGager™平臺開發的TCE具有更長的半衰期，可以減少給藥頻率，提高臨牀便利性。
公司的領先TCE項目ATG-201是基於CD19 x CD3的第二代TCE，用於治療B細胞相關自身免疫性疾病。ATG-201已完成CMC上遊開發，預計於2025年第3季度完成臨牀試驗申請(IND)申報準備工作。除ATG-201以外，公司的TCE管線還包括ATG-102，一款用於急性髓系白血病和慢性粒單核細胞白血病的LILRB4 x CD3 TCE；ATG-106，一款用於卵巢癌和腎癌的CDH6 x CD3 TCE；ATG-107，一款用於急性髓系白血病的FLT3 x CD3 TCE；和ATG-110，一款用於微衛星穩定 (MSS)結直腸癌的LY6G6D x CD3 TCE。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
